Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
CSL ( (AU:CSL) ) just unveiled an update.
CSL Limited announced the cessation of 8,790 securities due to the lapse of conditional rights, as the conditions were not met or became incapable of being satisfied. This cessation reflects a specific adjustment in the company’s issued capital, potentially impacting shareholder value and market perception of the company’s securities management.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$310.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
More about CSL
CSL Limited operates in the biotechnology industry, focusing on the development and delivery of innovative medicines and therapies. The company is known for its work in the areas of immunology, hematology, and vaccines, serving a global market with a strong emphasis on research and development.
Average Trading Volume: 913,931
Technical Sentiment Signal: Sell
Current Market Cap: A$120B
See more insights into CSL stock on TipRanks’ Stock Analysis page.